Study identifier:SH-TPO-0012
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
EXULT KNEE: Optimization of Dose (Study A) and Confirmation of Safety and Efficacy (Study B) of H 376/95 (Oral Direct Thrombin Inhibitor ximelagatran) Compared to Warfarin (COUMADIN) for the Prevention of Venous Thromboembolism Following Total Knee Arthroplasty
venous thromboembolism
Phase 3
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|